ETX.L

e-therapeutics plc [ETX.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ETX.L Stock Summary

In the News

ETX.L Financial details

Company Rating
-
Market Cap
76.09M
Income
-19.15M
Revenue
635K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
34
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-15.35
Forward P/E
-
PEG
-1.35
P/S
369.54
P/B
2.49
P/C
-
P/FCF
-20.25
Quick Ratio
19.47
Current Ratio
22.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.04
EPS next Y
-
EPS next Q
-
EPS this Y
-6.67%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
0.66%
Revenue last 5Y
60.93%
Revenue Q/Q
-11.11%
EPS Q/Q
20%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-15%
ROE
70%
ROC
-0.21%
Gross Margin
100%
Oper. Margin
-3158%
Profit Margin
-2479%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
8.0-24.0
52W High
-
52W Low
-
RSI
-
Rel Volume
5.86
Avg Volume
464.05K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.425
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
NVD.DE
AMZ.DE
VFINX
FXAIX
TL0.DE
Same Sector
GNOW
950210.KS
PMCB
EQ
MKKGY
Check Those
STG
0637.HK
ARYE
603737.SS
PFTA
Similar Market Cap
AWAY
0689.HK
RSID3.SA
CAGS.TO
FIVA

Company Profile

Healthcare Biotechnology
  • Volume Average 464.05K
  • Market Capitalization 76.09M
  • Employee 34
  • CEO Mr. Ahmad Ali Mortazavi
  • Headquarters London,GB
  • IPO Date 2007-11-28
  • Website https://www.etherapeutics.co.uk

e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.